1. Home
  2. ZYME vs DEI Comparison

ZYME vs DEI Comparison

Compare ZYME & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.11

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$12.48

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
DEI
Founded
2003
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2022
2006

Fundamental Metrics

Financial Performance
Metric
ZYME
DEI
Price
$26.11
$12.48
Analyst Decision
Strong Buy
Hold
Analyst Count
11
8
Target Price
$38.90
$12.94
AVG Volume (30 Days)
625.3K
2.2M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
7.06%
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
$105,965,000.00
$1,003,982,000.00
Revenue This Year
$183.10
$1.70
Revenue Next Year
N/A
$2.35
P/E Ratio
N/A
N/A
Revenue Growth
38.87
1.77
52 Week Low
$11.86
$9.04
52 Week High
$29.75
$16.94

Technical Indicators

Market Signals
Indicator
ZYME
DEI
Relative Strength Index (RSI) 63.53 63.71
Support Level $22.44 $11.15
Resistance Level $26.75 $12.58
Average True Range (ATR) 1.11 0.39
MACD 0.40 0.01
Stochastic Oscillator 84.13 96.93

Price Performance

Historical Comparison
ZYME
DEI

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.

Share on Social Networks: